Cadila Pharmaceuticals Launches ‘Silej Trio’: A Game-Changer in India’s Fight Against Hypertension

Cadila Pharmaceuticals Launches ‘Silej Trio’: A Game-Changer in India’s Fight Against Hypertension
 By Prem Kumar Sat, 11 Apr 2026
sffdg
Mumbai | April 11, 2026: In a major breakthrough for cardiovascular healthcare in India, Cadila Pharmaceuticals has introduced an innovative triple-drug combination therapy named ‘Silej Trio’. Designed to tackle the growing crisis of high blood pressure, this "three-in-one" pill aims to improve patient compliance and provide superior control over persistent hypertension.

The Burden of Hypertension in India

With nearly 220 million people in India suffering from high blood pressure, the challenges of late diagnosis and "pill burden" (taking multiple medications daily) often lead to poor treatment results. ‘Silej Trio’ addresses this by consolidating three globally recognized medications into a single, fixed-dose tablet, simplifying the daily routine for long-term patients.

How the Triple Action Works

The strength of Silej Trio lies in its sophisticated integration of three key drugs—Cilnidipine, Telmisartan, and Metoprolol. This combination stabilizes the heart and blood vessels through a multi-pronged clinical approach:

  • Vessel Relaxation: Opens up the blood vessels to allow smoother blood flow.

  • Hormonal Regulation: Balances the body's natural systems that drive up pressure.

  • Heart Rate Stabilization: Ensures the heart pumps efficiently without overexertion.

Better Results, Fewer Side Effects

One of the most significant advantages of this new therapy is its improved tolerability. Unlike many conventional BP treatments that often cause uncomfortable side effects, Silej Trio claims a significantly lower risk of peripheral edema (leg swelling), making it a more comfortable long-term option for those battling chronic cardiovascular issues.

Tags

From around the web